

\$%^STN;HighlightOn=;HighlightOff=;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9 MAR 22 EMBASE is now updated on a daily basis
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17 MAY 11 KOREPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT <http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

FILE 'HOME' ENTERED AT 07:54:18 ON 18 MAY 2006

FILE 'REGISTRY' ENTERED AT 07:54:27 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0
DICTIONARY FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.


* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/reqprops.html>

```
=>  
Uploading C:\Program Files\Stnexp\Queries\10536729\10536729a.str
```



chain nodes :
 18 19 25 27 28

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 20 21 22 23 24

chain bonds :

1-7 4-20 10-13 14-18 16-19 19-25 22-27 27-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-17

14-15 15-16 16-17 20-21 20-24 21-22 22-23 23-24

exact/norm bonds :

10-13 13-14 13-17 14-15 14-18 15-16 16-17 19-25 20-21 20-24 21-22 22-23

23-24 27-28

exact bonds :

1-7 4-20 16-19 22-27

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

G1:O,N,Hy

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS 27:CLASS 28:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS


L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10536729\10536729b.str



chain nodes :

```

18 19 25 27 28 30
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 20 21 22 23 24
chain bonds :
1-7 4-20 10-13 14-18 16-19 19-25 22-27 24-30 27-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-17
14-15 15-16 16-17 20-21 20-24 21-22 22-23 23-24
exact/norm bonds :
4-20 10-13 13-14 13-17 14-15 14-18 15-16 16-17 19-25 20-21 20-24 21-22
22-23 23-24 24-30 27-28
exact bonds :
1-7 16-19 22-27
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

```

G1:O, N, Hy

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS 27:CLASS 28:CLASS 30:CLASS

L2 STRUCTURE UPLOADED

=> d
L2 HAS NO ANSWERS
L2 STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10536729\10536729c.str

```

chain nodes :
18 24 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 19 20 21 22 23
chain bonds :
1-7 4-19 10-13 16-18 18-24 21-26 26-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-17
14-15 15-16 16-17 19-20 19-23 20-21 21-22 22-23
exact/norm bonds :
13-14 13-17 14-15 15-16 16-17 18-24 19-20 19-23 20-21 21-22 22-23 26-27
exact bonds :
1-7 4-19 10-13 16-18 21-26
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

```

G1:O,N,Hy

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS 26:CLASS 27:CLASS

L3 STRUCTURE UPLOADED

=> d
L3 HAS NO ANSWERS
L3 STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 07:55:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 11 TO ITERATE

100.0% PROCESSED 11 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 22 TO 418
PROJECTED ANSWERS: 2 TO 124

L4 2 SEA SSS SAM L1

=> s 11 full
FULL SEARCH INITIATED 07:55:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 301 TO ITERATE

100.0% PROCESSED 301 ITERATIONS 64 ANSWERS
SEARCH TIME: 00.00.01

L5 64 SEA SSS FUL L1

=> s 12
SAMPLE SEARCH INITIATED 07:56:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 28 TO ITERATE

100.0% PROCESSED 28 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 243 TO 877
PROJECTED ANSWERS: 7 TO 298

L6 7 SEA SSS SAM L2

=> s 12 full
FULL SEARCH INITIATED 07:56:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 535 TO ITERATE

100.0% PROCESSED 535 ITERATIONS 184 ANSWERS
SEARCH TIME: 00.00.01

L7 184 SEA SSS FUL L2

```
=> s 13
SAMPLE SEARCH INITIATED 07:56:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 0 TO 0
```

L8 0 SEA SSS SAM L3

```
=> s 13 full
FULL SEARCH INITIATED 07:56:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 187 TO ITERATE
```

```
100.0% PROCESSED 187 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01
```

L9 4 SEA SSS FUL L3

```
=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
                           ENTRY SESSION
FULL ESTIMATED COST      501.70 501.91
```

```
FILE 'CAPLUS' ENTERED AT 07:57:09 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 May 2006 VOL 144 ISS 21
FILE LAST UPDATED: 16 May 2006 (20060516/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 19

L10 1 L9

=> s 17

L11 4 L7

=> s 15

L12 4 L5

=> d ibib abs hitstr tot

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssptaylc1626

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9 MAR 22 EMBASE is now updated on a daily basis
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17 MAY 11 KOREAPAT updates resume

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT <http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

FILE 'HOME' ENTERED AT 07:54:18 ON 18 MAY 2006

FILE 'REGISTRY' ENTERED AT 07:54:27 ON 18 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0
DICTIONARY FILE UPDATES: 16 MAY 2006 HIGHEST RN 884586-69-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/reqprops.html>

```
=>
Uploading C:\Program Files\Stnexp\Queries\10536729\10536729a.str
```

L1 STRUCTURE UPLOADED

```
=> d
L1 HAS NO ANSWERS
L1          STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
```

Structure attributes must be viewed using STN Express query preparation.

```
=>
Uploading C:\Program Files\Stnexp\Queries\10536729\10536729b.str
```

```
L2      STRUCTURE UPLOADED
```

```
=> d
L2 HAS NO ANSWERS
L2          STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
```

Structure attributes must be viewed using STN Express query preparation.

```
=>
Uploading C:\Program Files\Stnexp\Queries\10536729\10536729c.str
```

```
L3      STRUCTURE UPLOADED
```

```
=> d
L3 HAS NO ANSWERS
L3          STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
```

Structure attributes must be viewed using STN Express query preparation.

```
=> s 11
SAMPLE SEARCH INITIATED 07:55:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      11 TO ITERATE
```

```
100.0% PROCESSED      11 ITERATIONS          2 ANSWERS
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                           BATCH   **COMPLETE**
PROJECTED ITERATIONS:    22 TO      418
PROJECTED ANSWERS:        2 TO       124
```

```
L4      2 SEA SSS SAM L1
```

```
=> s 11 full
FULL SEARCH INITIATED 07:55:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      301 TO ITERATE
```

```
100.0% PROCESSED      301 ITERATIONS          64 ANSWERS
SEARCH TIME: 00.00.01
```

```
L5      64 SEA SSS FUL L1
```

```
=> s 12
SAMPLE SEARCH INITIATED 07:56:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      28 TO ITERATE
```

```
100.0% PROCESSED      28 ITERATIONS          7 ANSWERS
SEARCH TIME: 00.00.01
```

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 243 TO 877
PROJECTED ANSWERS: 7 TO 298

L6 7 SEA SSS SAM L2

=> s 12 full
FULL SEARCH INITIATED 07:56:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 535 TO ITERATE

100.0% PROCESSED 535 ITERATIONS 184 ANSWERS
SEARCH TIME: 00.00.01

L7 184 SEA SSS FUL L2

=> s 13
SAMPLE SEARCH INITIATED 07:56:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 0 TO 0

L8 0 SEA SSS SAM L3

=> s 13 full
FULL SEARCH INITIATED 07:56:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 187 TO ITERATE

100.0% PROCESSED 187 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01


L9 4 SEA SSS FUL L3

Not ODP

L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:342903 CAPLUS
 DOCUMENT NUMBER: 144:390904
 TITLE: Phenyl-substituted oxazolidinone derivatives and
 their preparation, pharmaceutical compositions, and use as
 antimicrobials
 INVENTOR(S): Das, Biswajit; Ahmed, Shahadat; Yadav, Ajay Singh;
 Ghosh, Soma; Gujrati, Arti; Sharma, Pankaj; Rattan,
 Ashok
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
 SOURCE: PCT Int. Appl., 145 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006038100	A1	20060413	WO 2005-IB2971	20051006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NQ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:	US 2004-616964P	P 20041008		

GI



AB The invention relates to phenyl-substituted oxazolidinones I, or their pharmaceutically acceptable salts, solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, prodrugs, or metabolites, as well as processes for their synthesis. In compds. I: A is pyridine-2,5-diyi,

L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 pyrimidine-2,5-diyi, furan-2,5-diyi, thiophene-2,5-diyi, and analogs; U and V are independently selected from H (both U and V cannot be H), lower alkyl, or halo; R is CH:NRf, CH:NC(O)Rf, CH:NRORf, CH:NC(O)NRHf, heterocyclyl, or heteroaryl; Rf is H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; R1 is azido, NCS, NHYR, NRjC(T)NRfRq, NRfRq, NRj(C:O)Rf; Y is (C:O), (C:S), or SO2; T is O, S, N(CN), N(NO2), CH(NO2);

R1 is H, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, heteroarylalkyl, heterocyclylalkyl; Rq is H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclylalkyl; Rs is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroarylalkyl or heterocyclylalkyl, with the proviso that:

when U is H, V is F, R is NHCOCH3 and A is pyridine-2,5-diyi, then R is a 5-membered heterocyclic ring contg. two or four N atoms (wherein the 5-membered heterocyclic ring contg. four N atoms is linked through an

N-atom to pyridine-2,5-diyi and is always substituted); when A is Pyrimidine-2,5-diyi and U, V, and R1 are as defined above then R cannot be

a 5-membered heterocyclyl ring contg. 2 hetero atoms. The invention also relates to pharmaceutical compns. contg. I as antimicrobials. I are useful antimicrobial agents (no data), effective against a no. of human and veterinary pathogens, including gram-pos. aerobic bacteria (for example, multiple-resistant staphylococci, streptococci, and enterococci),

as well as anaerobic organisms (for example, *Bacteroides* spp. and *Clostridium* spp.), and acid fast organisms (for example, *Mycobacterium tuberculosis*, *Mycobacterium avium* and *Mycobacterium* spp.). Approx. 100 compds. I were prep'd., and are claimed by name. The synthesis of most compds. I and a variety of intermediates is described. For instance, 5-bromopyridin-2-amine was (1) N-protected with BOC, followed by (2) conversion of the bromide to the boronic acid, (3) Pd-catalyzed coupling of the boronic acid with (S)-N-[13-(4-ido-3,5-difluorophenyl)-2-oxo-5-oxazolidinyl]methylacetamide, (4) N-deprotection with HCl, and (5) cyclization of the freed amine with 2,3-dimethoxytetrahydrobutan-3-carboxaldehyde, to give invention compd. II. I have good activity

against multiply resistant Gram-pos. pathogens like methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant Enterococci (VRE), and Streptococci pneumoniae. Some have activity against multiple drug-resistant tuberculosis (MDR-TB) strain, while others have

significant activity against important anaerobic bacteria. I are also active against *Mai* sires and Gram-neg. pathogens like *Moraxella catarrhalis* and *Haemophilus influenzae*.

IT 883229-93-4P, N-[3-(2,3'-Difluoro-4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methylacetamide 883230-18-0, N-[(5S)-2-Oxo-3-(2,3',6'-trifluoro-4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)biphenyl-4-yl)-1,3-oxazolidin-5-yl]methylacetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of phenyl-substituted oxazolidinone

derivs. as antimicrobials)

RN 883229-93-4 CAPLUS


CN Acetamide, N-[3-(4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2,3'-6-trifluoro[1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 difluoro[1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 883230-18-0 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2,3',6-trifluoro[1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L12 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 2004:467906 CAPLUS
 141:38595

Preparation of oxazolidinone/isoxazoline derivatives as antibacterial agents


INVENTOR(S): Carrangue, Daniel Robert; Gravestock, Michael Barry; Hales, Neil James; Hauck, Sheila Irene; Weber, Thomas Peter

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 185 pp.
 CODEN: PIXKD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2004048392	A1	20040610	WO 2003-GB5087	20031124	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NQ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
TG	CA 2507468	AA	20040610	CA 2003-2507468	20031124
AU 2003302404	A1	20040618	AU 2003-302404	20031124	
EP 1567532	A1	20050831	EP 2003-811807	20031124	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003016688	A	20051018	BR 2003-16688	20031124	
CN 1742015	A	20060301	CN 2003-80109196	20031124	
JP 2006508192	T2	20060309	JP 2005-510253	20031124	
NO 2005002534	A	20050822	NO 2005-2534	20050526	
PRIORITY APPLN. INFO.:			GB 2002-27702	A 20021128	
			GB 2003-4725	A 20030301	
			GB 2003-18608	A 20030808	
			WO 2003-GB5087	W 20031124	

OTHER SOURCE(S): MARPAT 141:38595
 GI



AB Title compds. (R1a)m-A-C-B-CH2-R1b [C = biaryl group; A, B = dihydroisoxazole, oxazolidinone; R1a = CN, carboxy, alkoxycarbonyl, aryl, etc.; m = 0-2; R1b = OH, silyloxy, etc.; I] are prepared. For instance, (SR)-3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (preparation given) is coupled to 5,5-bis[(tert-butylidemethylsilyloxy)methyl]-4-(trimethylstannyl)phenyl]-4,5-dihydroisoxazole (preparation given) (NMP, (furan-2-yl)3P, dba3Pd2) and the

resulting adduct desilylated (THF, TBAF) to give II. II exhibits MIC = 0.5 μ g/mL against *Staphylococcus aureus*; compds. of the invention are antibacterial agents.


IT 702679-77-4P, (SR)-3-[4'-(5,5-Bis[(tert-Butylidemethylsilyloxy)methyl]-4,5-dihydroisoxazol-3-yl)-2-fluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702679-98-9P, (SR)-3-[4'-(5,5-Bis[(tert-Butylidemethylsilyloxy)methyl]-4,5-dihydroisoxazol-3-yl)-2-fluoro-1,1'-biphenyl-4-yl]-5-(4-methyl-1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of oxazolidinone/isoxazoline derivs. as antibacterial agents)

RN 702679-77-4 CAPLUS

CN 2-Oxazolidinone, 3-[4'-(5,5-bis[(1,1-dimethylsilyl)dimethylsilyloxy]methyl)-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702679-98-9 CAPLUS

CN 2-Oxazolidinone, 3-[4'-(5,5-bis[(1,1-dimethylsilyl)dimethylsilyloxy]methyl)-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-(4-methyl-1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 702679-95-6P, (SR)-3-[4'-(5,5-Bis(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-2-fluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702680-03-3P,

(5R)-3-[4'-(5,5-Bis(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-2-fluoro-1,1'-biphenyl-4-yl]-5-(4-methyl-1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one 702680-06-6P, N-[(5S)-3-[4'-(5,5-Bis(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-ylmethyl]acetamide 702680-23-7P, (SR)-3-[4'-(5,5-


Bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-2,2'-difluoro-1,1'-biphenyl-4-

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of oxazolidinone/isoxazoline derivs. as antibacterial agents)

RN 702679-95-6 CAPLUS

CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-03-3 CAPLUS

CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-(4-methyl-1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-06-6 CAPLUS

CN Acetamide, N-[(5S)-3-[4'-(4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl)-1,1'-biphenyl-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 702680-23-7 CAPLUS


CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702680-35-1 CAPLUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702681-75-2 CAPLUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(1,2,5-thiadiazol-3-ylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 oxo-1,3-oxazolidin-5-yl)methyl](1,2,5-thiadiazol-3-yl)carbamate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of oxazolidinone/oxazoline derivs. as antibacterial agents)
 RN 702680-25-9 CAPLUS
 CN 2-Oxazolidinone,
 3-[4'-(5,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl)-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 702680-37-3 CAPLUS
 CN 2-Oxazolidinone,
 3-[4'-(5,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl)-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 702681-77-4 CAPLUS




IT 702680-09-9, (5S)-3-[4'-(5,5-Bis[[(tert-butylidimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl)-2-fluoro-1,1'-biphenyl-4-yl]-5-(acetamidomethyl)-1,3-oxazolidin-2-one
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of oxazolidinone/oxazoline derivs. as antibacterial agents)

RN 702680-09-9 CAPLUS

CN Acetamide,
 N-[{(5S)-3-[4'-(5,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl)-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 702680-25-0P, (5R)-3-[4'-(5,5-Bis[[(tert-butylidimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl)-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one
 702680-37-3P, (5R)-3-[4'-(5,5-Bis[[(tert-butylidimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl)-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(4-(fluoromethyl)-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
 702681-77-4P, tert-Butyl [(5S)-3-[4'-(5,5-bis(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-2,2'-difluorobiphenyl-4-yl]-2-

L12 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Carbamic acid, [(5R)-3-[4'-(4,5-dihydro-5,5-bis(hydroxymethyl)-3-isoxazolyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-1,2,5-thiadiazol-3-yl-, 1,1-dimethylsylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:


4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L12 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:67887 CAPLUS
 DOCUMENT NUMBER: 141:23522
 TITLE: Preparation of isoxazolinyloxazolidinone
 INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 78 pp.
 CODEN: PIIXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048370	A1	20040610	WO 2003-GB5082	20031124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SE, SG, SK, SL, SY, TJ, TM, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1567521	A1	20050831	EP 2003-811806	20031124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			GB 2002-27701	A 20021128
			WO 2003-GB5082	W 20031124


OTHER SOURCE(S): MARPAT 141:23522
 GI



AB Isoxazolinyloxazolidinone compds. of formula I (R1CH2-A-C-B-CH2R2 [A, B = oxazolidinone, isoxazoline; C = (substituted) biaryl group; R1, R2 = OH, trialkylsilyloxy, acyloxy, heteroaryl, etc.]) are prepared as antibacterial agents. Methods for making compds. of formula I, compns. containing them and their use as antibacterial agents are also described. Thus, II was prepared, and had MIC of 0.5 µg/mL against *Staphylococcus aureus*.
 IT 698981-84-9P 698981-94-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic


L12 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 698981-89-4 CAPLUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 698981-99-6 CAPLUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2,3'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Current application


ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Preparation; THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of isoxazolinyloxazolidinone antibacterial agents)
 RN 698981-84-9 CAPLUS
 CN 2-Oxazolidinone, 3-[4'-(5-[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-4,5-dihydro-3-isoxazolyl)-2-fluoro-3'-methoxy[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 698981-94-1 CAPLUS
 CN 2-Oxazolidinone, 3-[4'-(5-[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-4,5-dihydro-3-isoxazolyl)-2,3'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 698981-89-4P 698981-99-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of isoxazolinyloxazolidinone antibacterial agents)

ODP

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:221667 CAPLUS
 DOCUMENT NUMBER: 138:238171
 TITLE: Preparation of oxazolidinones and/or isoxazolines as antibacterial agents
 INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Swain, Michael Lingard; Hauck, Sheila Irene; Mills, Stuart Dennett
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 127 pp.
 CODEN: PIIXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022824	A1	20030320	WO 2002-GB4120	20020909
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459766	AA	20030320	CA 2002-2459766	20020909
EP 1427711	A1	20040616	EP 2002-765019	20020909
EP 1427711	B1	20050713		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012458	A	20041019	BR 2002-12458	20020909
JP 2005507386	T2	20050317	JP 2003-526899	20020909
US 2005107435	A1	20050519	US 2003-489266	20020909
NZ 531621	A	20050624	NZ 2002-531621	20020909
CN 1639136	A	20050713	CN 2002-822327	20020909
AT 295502	E	20050715	AT 2002-765019	20020909
PT 1427711	T	20051130	PT 2002-765019	20020909
ES 2244802	T3	20051216	ES 2002-2765019	20020909
ZA 2004001888	A	20050418	ZA 2004-1888	20040308
NO 2004001428	A	20040608	NO 2004-1428	20040405
HK 1065789	A1	20051230	HK 2004-108506	20041029
PRIORITY APPLN. INFO.:			GB 2001-21942	A 20010911
			GB 2002-15420	A 20020704
			WO 2002-GB4120	W 20020909

OTHER SOURCE(S): MARPAT 138:238171
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB: Oxazolidinones and isoxazolines (shown as I; variables defined below; e.g.

102(e)

1

DP


FD 11/24/03

PRD 11/28/02

102(e)

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN


(Continued)



9/9/02


RN 501940-61-0 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(5R)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-64-3 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(5S)-4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 501939-97-5, (SR)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of oxazolidinones and/or isoxazolines as antibacterial agents)

RN 501939-97-5 CAPLUS


CN 2-Oxazolidinone,

3-[4'-[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]- (5R)- (9CI) (CA INDEX NAME)

(CA INDEX NAME)

(CA INDEX NAME)

Absolute stereochemistry.




IT 501940-00-7P, N-[(5S)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl]acetamide
 501940-10-9P, N-[(5S)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl]acetamide
 501940-19-8P, (5R)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-20-1P,

(5R)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 501940-67-6 CAPLUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(3-isoxazolylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-72-3 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(4,5-dihydro-5-[(phosphonoxy)methyl]-3-isoxazolyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



•2 Na

RN 501940-90-5 CAPLUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(3-isoxazolylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 oxazolidin-2-one 501940-21-2P, tert-Butyl-N-[(5R)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl]acetamide 501940-22-3P, (5R)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2'-fluoro-1,1'-biphenyl-4-yl]-5-[(3-isoxazolylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)

dihydroisoxazol-3-yl]-2'-fluoro-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl]acetamide 501940-63-4P, N-[(5S)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one 501940-62-1P, N-[(5S)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl]acetamide 501940-65-4P, N-[(5S)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl]acetamide 501940-68-7P, tert-Butyl-N-[(5R)-3-[2-fluoro-4'-[5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl]acetamide, N-[(5S)-3-[2-fluoro-4'-[5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl]acetamide, N-[(5S)-3-[4'-[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 501940-00-7P, N-[(5S)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl]acetamide
 RN 501940-00-7 CAPLUS
 CN Acetamide,

N-[(5S)-3-[4'-[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 501940-10-9 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (5S,5S)-N-[3-(4'-[5-(acetylaminomethyl)-2-oxooxazolidin-3-yl]-2,2'-difluorobiphenyl-4-yl)-2-oxooxazolidin-5-ylmethyl]acetamide (shown as II), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, which useful as antibacterial agents, processes for their manuf. and pharmaceutical compns. contg. them are described. For I: C is for example III, IV, V; wherein A and B = 2-oxooxazolidin-3-yl, 2-isoxazolin-3-yl; R2a to R3b = H and F; R1a and R1b =, for example, hydroxy, -NHC(W)R4, NH(HET-1) and HET-2; wherein W is O or S; R4 is, for example, H, amino, (1-4C)alkyl; HET-1 is, for example, a C-linked 5-membered heterocyclic ring; HET-2 is, for example, an N-linked 5-membered,

5-membered, fully or partially unsatd. heterocyclic ring. I have good activity against a broad range of Gram-pos. pathogens including organisms known to be resistant to most commonly used antibiotics, together with activity against fastidious Gram neg. pathogens such as *H. influenzae*, *M. catarrhalis*, *Mycoplasma* and *Chlamydia* strains. The min. inhibitory concns. of II for methicillin sensitive and quinolone sensitive *Staphylococcus aureus*, methicillin resistant and quinolone resistant *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Haemophilus influenzae*, and *Moraxella catarrhalis* are 0.25, 0.5, 0.06, 0.13, 2.0 and 0.5 μ g/mL, resp. Preps. of 64 examples of I and many intermediates are included. For example, I was prep'd. as follows:

(5S)-N-[3-(3-fluoro-4-iodophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (0.4 mmol) and Bu4NBr (0.4 mmol) were stirred in a mixt. of DMF (0.5 mL) and NEt3 (2 mmol), and degassed by bubbling N₂. Pd(II) acetate (0.04 mmol)

was added, and the whole heated at 70° for 18 h. Workup gave the desired product (47 mg). Nine examples of pharmaceutical dosage forms are

tabulated.

IT 501939-86-2P, N-[(5S)-3-(4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-ylmethyl-N-(isoxazol-3-yl)carbamate 501939-91-9P, tert-Butyl N-[(5R)-3-[4'-[5-[(tert-butylidimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-2-fluoro-4'-[(hydroxymethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-ylmethyl-N-(isoxazol-3-yl)carbamate

501940-39-2P, (5R)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-ylmethyl-N-(isoxazol-3-yl)-1,3-triazol-1-ylmethyl]-1,3-oxazolidin-2-one 501940-43-8P,

(5R)-3-[4'-[5-[(tert-Butyldimethylsilyl)oxy]methyl]-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-69-8P, {3-[4'-[5S]-5-[(Acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl}-4,5-dihydroisoxazol-5-ylmethyl di-tert-butyl phosphate 501940-71-2P, {3-[4'-[5S]-5-[(Acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl}-4,5-dihydroisoxazol-5-ylmethyl dihydrogen phosphate

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of oxazolidinones and/or isoxazolines as antibacterial agents)


RN 501939-86-2 CAPLUS

CN Acetamide,

N-[(5S)-3-[4'-[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 1)-4,5-dihydro-3-isoxazolyl)-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501939-90-8 CAPLUS

CN Carbamic acid, {[(5R)-3-[4'-[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-91-9 CAPLUS

CN Carbamic acid, {[(5R)-3-[4'-[4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl]-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 501940-39-2 CAPLUS

CN 2-Oxazolidinone,

3-[4'-[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-43-8 CAPLUS

CN 2-Oxazolidinone,

3-[4'-[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4,5-dihydro-3-isoxazolyl]-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 501940-69-8 CAPLUS

CN Phosphoric acid, {3-[4'-[5S]-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-1,1'-biphenyl]-4-yl}-4,5-dihydro-5-isoxazolyl)methyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501940-71-2 CAPLUS


CN Acetamide, N-[(5S)-3-[4'-[4,5-dihydro-5-(phosphonooxy)methyl]-3-isoxazolyl]-1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501939-85-1P, [(5R)-3-[2-Fluoro-4'-(5'-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl acetate 501939-89-5P, N-[(5S)-3-[4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 501939-92-0P, (5S)-3-[2-Fluoro-4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-5-[(isoxazol-3-ylamino)methyl]-3-oxazolidin-2-one 501939-96-4P, (5R)-3-[2-Fluoro-4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501939-99-7P, N-[(5S)-3-[4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 501940-01-0P, (5R)-3-[2-Fluoro-4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-4,5-dihydroisoxazol-5-yl]acetamide 501940-04-1P, N-[(3-[2,2'-Difluoro-4'-(5-(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-2-one 501940-06-3P, N-[(5S)-3-[2,2'-Difluoro-4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-4,5-dihydroisoxazol-5-yl)methyl]acetamide 501940-09-6P, N-[(5S)-3-[2,2'-Difluoro-4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 501940-11-0P, (5R)-3-[2,2'-Difluoro-4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-12-1P, (5R)-3-[2,2'-Difluoro-4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-13-2P, tert-Butyl N-[(5R)-3-[2,2'-Difluoro-4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]N-[(isoxazol-3-yl)carbamate 501940-14-3P, (5R)-3-[2,2'-Difluoro-4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one 501940-15-4P, N-[(5S)-3-[2,2'-Difluoro-4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 501940-41-6P, (5R)-3-[1H-1,2,3-Triazol-1-ylmethyl]-3-[4'-(5-(1H-1,2,3-triazol-1-ylmethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one 501940-42-7P, (5R)-3-[2-Fluoro-4'-(5-(1H-1,2,3-triazol-1-ylmethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-ylmethyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-

Absolute stereochemistry.



RN 501939-92-0 CAPLUS
CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(3-isoxazolylamino)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501939-96-4 CAPLUS
CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

[1-(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-44-9P, N-[(5S)-3-[2-Fluoro-4'-(5-(1H-1,2,3-triazol-1-yl)methyl)-4,5-dihydroisoxazol-3-yl)methyl]acetamide 501940-46-1P, (5R)-3-[4'-(5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-48-3P, (5R)-3-[4'-(5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-50-7P, N-[(5S)-3-[2-Fluoro-4'-(5-(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-54-1P, (5R)-3-[2-Fluoro-4'-(5-(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one 501940-59-6P, (5R)-3-[2-Fluoro-4'-(5-(hydroxymethyl)-4,5-

dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one 501940-59-6P, (5R)-3-[2-Fluoro-4'-(5-(hydroxymethyl)-4,5-


dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-61-0P, N-[(5S)-3-[4'-(5-(SR)-5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-2-one 501940-63-3P, N-[(5S)-3-[4'-(5-(Hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-2-one 501940-67-6P, (5S)-3-[2-Fluoro-4'-(5-(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-4,5-dihydroisoxazol-3-yl]-1,1'-biphenyl-4-yl]-5-[(isoxazol-3-ylamino)methyl]-3-oxazolidin-2-one 501940-72-3P, [3-[4'-(Acetylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-4,5-dihydroisoxazol-5-yl]methyl disodium phosphate 501940-90-5P, (5S)-3-[2,2'-Difluoro-4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-5-[(isoxazol-3-ylamino)methyl]-3-oxazolidin-2-one 501940-91-0P, (5R)-3-[2,2'-Difluoro-4'-(5-(hydroxymethyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-5-[(isoxazol-3-ylamino)methyl]-3-oxazolidin-2-one

RL: PA (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological activity); PREP (Preparation); USES (Uses)


(drug candidate; prepn. of oxazolidinones and/or isoxazolines as antibacterial agents)

RN 501939-05-1 CAPLUS
CN 2-Oxazolidinone, 5-[(Acetyloxy)methyl]-3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-89-5 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-1,1'-biphenyl-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 501939-99-7 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-01-8 CAPLUS
CN Acetamide, N-[(5S)-3-[2-Fluoro-4'-(5-(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-4,5-dihydro-5-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-04-1 CAPLUS
 CN Acetamide, N-[3-[2,2'-difluoro-4'-(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-4,5-dihydro-5-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-06-3 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(4,5-dihydro-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-isoxazolyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-09-6 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-11-0 CAPLUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]- (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-12-1 CAPLUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-13-2 CAPLUS
 CN Carbamic acid, [(5R)-3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-14-3 CAPLUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2'-fluoro[1,1'-biphenyl]-4-yl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-15-4 CAPLUS
 CN Acetamide,
 N-[(5S)-3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2'-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501940-41-6 CAPLUS

CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl)-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501940-42-7 CAPLUS

CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501940-44-9 CAPLUS

CN Acetamide, N-[(5S)-3-[4'-(4,5-dihydro-5-(1H-1,2,3-triazol-1-ylmethyl)-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501940-46-1 CAPLUS

CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501940-48-3 CAPLUS

CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-1,1'-biphenyl-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501940-50-7 CAPLUS

CN Acetamide, N-[(5S)-3-[4'-(4,5-dihydro-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501940-54-1 CAPLUS

CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 501940-59-6 CAPLUS

CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-(hydroxymethyl)-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-19-8 CAPLUS
 CN 2-oxazolidinone,
 3-[4'-(5-[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-
 4,5-dihydro-3-isoxazolyl]-2',2'-difluoro[1,1'-biphenyl]-4-yl]-5-[(4-methyl-
 1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 501940-20-1 CAPLUS
 CN 2-oxazolidinone,
 3-[4'-(5-[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-
 4,5-dihydro-3-isoxazolyl]-2',2'-difluoro[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-
 triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-21-2 CAPLUS
 CN Carbamic acid,
 [(5R)-3-(4'-(5-[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl)-
 4,5-dihydro-3-isoxazolyl]-2',2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-
 oxazolidinyl)methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA
 INDEX NAME)
 Absolute stereochemistry.




RN 501940-22-3 CAPLUS
 CN 2-oxazolidinone,
 3-[4'-(5-[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-
 4,5-dihydro-3-isoxazolyl]-2'-fluoro[1,1'-biphenyl]-4-yl]-5-(hydroxymethyl)-
 , (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-23-4 CAPLUS
 CN Acetamide,
 N-[(5S)-3-(4'-(5-[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl)-
 1]-4,5-dihydro-3-isoxazolyl]-2'-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-
 oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-56-3 CAPLUS
 CN 2-Oxazolidinone, 3-[4'-(4,5-dihydro-5-[(4-methyl-1H-1,2,3-triazol-1-
 yl)methyl]-3-isoxazolyl)-2-fluoro[1,1'-biphenyl]-4-yl]-5-[(1,1-
 dimethylethyl)dimethylsilyl]oxy)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-62-1 CAPLUS
 CN Acetamide,
 N-[(5S)-3-(4'-(5R)-5-[(1,1-dimethylethyl)dimethylsilyl]oxy)-
 methyl]-4,5-dihydro-3-isoxazolyl]-1,1'-biphenyl]-4-yl]-2-oxo-5-
 oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-65-4 CAPLUS
 CN Acetamide,
 N-[(5S)-3-(4'-(5S)-5-[(1,1-dimethylethyl)dimethylsilyl]oxy)-
 methyl]-4,5-dihydro-3-isoxazolyl]-1,1'-biphenyl]-4-yl]-2-oxo-5-
 oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-68-7 CAPLUS
 CN Carbamic acid, [(1S)-3-(4'-(4,5-dihydro-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-3-isoxazolyl)-2-fluoro(1,1'-biphenyl)-4-yl)-2-oxo-5-oxazolidinyl]methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


```
=> s 19
L13          1 L9
=> d ibib abs hitstr tot
```

L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 20061342903 CAPLUS
 DOCUMENT NUMBER: 144:390904
 TITLE: Phenyl-substituted oxazolidinone derivatives and
 their
 preparation, pharmaceutical compositions, and use as
 antimicrobials
 INVENTOR(S): Das, Biswajit; Ahmed, Shahadat; Yadav, Ajay Singh;
 Ghosh, Soma; Gujrati, Arti; Sharma, Pankaj; Rattan,
 Ashok
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
 SOURCE: PCT Int. Appl., 145 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


Duplicate

PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 2006038100 A1 20060413 WO 2006182971 20051006
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
 NA, NG, NI, NO, NQ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
 SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
 YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 PRIORITY APPLN. INFO.: US 2004-616964P P 20041008

GI



I




II

AB The invention relates to phenyl-substituted oxazolidinones I, or their pharmaceutically acceptable salts, solvates, esters, enantiomers,

L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Acetamide,
 N-[(5S)-2-oxo-3-(2,3',6-trifluoro-4'-(5S)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-5-oxazolidinylmethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 diastereomers, N-oxides, polymorphs, prodrugs, or metabolites, as well as processes for their synthesis. In compds. I: A is pyridine-2,5-diyi, pyrimidine-2,5-diyi, furan-2,5-diyi, thiophene-2,5-diyi, and analogs; U and V are independently selected from H (both U and V cannot be H), lower alkyl, or halo; R is CH:NOTR, CH:NOTC(O)R, CH:NOTR, CH:NOTC(O)NHR, heterocyclyl, or heteroaryl; R1 is H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; R1 is azido, NCS, NHVR, NR3Cl:TRN(R)R, NR3R, NR3R, NR3(C:O)OR; Y is (C:O), (C:S), or SO2; T is O, S, N(CN), N(NO2), CH(NO2);

Rj is H, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, heteroarylalkyl, or heterocyclylalkyl; Rq is H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl; Rz is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroarylalkyl or heterocyclylalkyl; with the proviso that:

when U is H, V is F, R is NHCOCH3 and A is pyridine-2,5-diyi, then R is a 5-membered heterocyclyl ring contg. two or four N atoms (wherein the 5-membered heterocyclyl ring contg. four N atoms is linked through an N-atom

to pyridine-2,5-diyi and is always substituted); when A is pyrimidine-2,5-diyi and U, V, and R1 are as defined above then R cannot be

a 5-membered heterocyclyl ring contg. 2 hetero atoms. The invention also relates to pharmaceutical compns. contg. I as antimicrobials. I are useful antimicrobial agents (no data), effective against a no. of human and veterinary pathogens, including gram-pos. aerobic bacteria (for example, multiple-resistant staphylococci, streptococci, and enterococci),

as well as anaerobic organisms (for example, *Bacteroides* spp. and *Clostridium* spp.), and acid fast organisms (for example, *Mycobacterium tuberculosis*, *Mycobacterium avium* and *Mycobacterium* spp.). Approx. 100 compds. I and a variety of intermediates is described. For instance, 5-bromopyridin-2-amine was (1) N-protected with BOC, followed by (2) conversion of the bromide to the boronic acid, (3) Pd-catalyzed coupling of the boronic acid with (S)-N-[(3-(4-iodo-3,5-difluorophenyl)-2-oxo-5-oxazolidinyl)methyl]acetamide, (4) N-deprotection with HCl, and (5) cyclization of the freed amine with 2,5-dimethoxytetrahydrofuran-3-carboxaldehyde, to give invention compnd. II. I have good activity

against multiply resistant Gram-pos. pathogens like methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant Enterococci (VRE), and *Streptococcus pneumoniae*. Some I have activity against multiple drug-resistant tuberculosis (MDR-TB) strain, while others have significant

activity against important anaerobic bacteria. I are also active against MAI sires and Gram-neg. pathogens like *Moraxella catarrhalis* and *Haemophilus influenzae*.

IT 883229-96-7, N-[(5S)-2-Oxo-3-[2,3',6-trifluoro-4'-(5S)-5-

(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]biphenyl-4-yl]-1,3-oxazolidin-5-yl)methyl]acetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate: preparation of phenyl-substituted oxazolidinone derivs. as antimicrobials)

RN 883229-96-7 CAPLUS

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:588234 CAPLUS
 DOCUMENT NUMBER: 141:140417

TITLE: Preparation of novel biphenyls, their intermediates, and their use as bactericides

INVENTOR(S): Shikawa, Sojiro; Ishikawa, Makoto; Yanagisawa, Yumiko; Kawaguchi, Masami; Fujita, Toshiaki; Machishi, Kazunori; Yoshida, Yatoshi

PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 185 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
 JP 2004203809 A2 20040722 JP 2002-376218 20021226

PRIORITY APPLN. INFO.: MARP141:140417 20021226

OTHER SOURCE(S): GI

Not a art

later than

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT

AB Title compds. I (R1-R8 = H, halo, NH2, glycylamino, (un)substituted alkoxy; T, Q = halo, OH, (un)substituted C1-8 alkoxy, (un)substituted C1-8 alkanoyloxy, NH2, N3, (un)substituted unsatd. heterocyclyl, etc.), useful for controlling (drug-resistant) bacteria, are prepared by conversion of 3-(substituted phenyl)-2-oxooxazolidines II (R1-R4, Q = same as above; X = iodine, Br, Cl, haloalkylsulfonyloxy, diaryl phosphate residue) into 3-(boron-substituted phenyl)-2-oxooxazolidines III (R1-R4, Q = same as above; X = Br9R10; R9, R10 = OH, Cl-8 linear alkyl(oxy), C3-8 branched alkyl(oxy); R9R10 may be linked), then coupling with oxazolidinylbenzenes III (R5-R8, T = same as above; Y = iodine, Br, Cl, haloalkylsulfonyloxy, diaryl phosphate residue). Thus, coupling of

3-(3-fluoro-4-iodophenyl)-2-oxo-5(R)-phthalimidomethyloxazolidine with 5(S)-acetamidomethyl-3-(3-fluoro-4-(4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-oxooxazolidine in the presence of K phosphate and tetrakis(triphenylphosphine)palladium in DMF gave the corresponding biphenyl compound with 66% yield, which showed MIC of 2 µg/ml against methicillin-resistant *Staphylococcus aureus*.

IT 501939-75-9P 627541-97-3P 627542-07-8P

627542-15-8P 627542-17-0P 627542-22-7P

627542-26-1P 627542-28-3P 627542-37-4P

627542-40-9P 627542-42-1P 627542-45-4P

627542-49-7P 627542-52-3P 627542-60-3P

627542-66-9P 627542-70-5P 627542-72-7P

627542-80-7P 627542-81-8P 627542-92-9P

627542-84-1P 627542-85-7P 627542-97-4P

627542-88-5P 627542-89-6P 627542-95-4P

627542-96-5P 627542-97-6P 724792-06-3P

724792-98-5P 724792-91-0P 724792-92-1P


724792-95-4P 724792-97-6P 724793-05-9P

FD

10/28/2003


L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 724793-10-6P 724793-19-5P 724793-21-9P
 724793-24-2P 724793-27-5P 724793-30-0P
 724793-33-3P 724793-36-6P 724793-39-9P
 724793-42-4P 724793-48-0P 724793-50-4P
 724793-61-7P 724793-66-2P 724793-69-5P
 724793-75-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (prepn. of (oxooxazolidinyl)biphenyls as bactericides for (drug-resistant) bacteria)
 RN 501939-75-9 CAPLUS
 CN Acetamide, N,N'-[(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627541-97-3 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627542-07-8 CAPLUS
 CN 11-Oxa-2,4,9-triazatridec-2-enoic acid, 8-[[[[(5S)-3-[4'-(5S)-5-(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]amino]carbonyl]-3-[(1,1-

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B


—NHAc

RN 627542-17-0 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-2-amino-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-16-9
 CMF C24 H25 F2 N5 O6

Absolute stereochemistry.




CM 2


L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 dimethylethoxy)carbonyl]amino]-12,12-dimethyl-10-oxo-, 1,1-dimethylethyl ester, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 627542-15-8 CAPLUS
 CN Carbamic acid, [2-[[[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CRN 76-05-1
 CMF C2 H F3 O2



RN 627542-22-7 CAPLUS
 CN Carbamic acid, [1-[[[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]amino]carbonyl]-1,2-ethanediyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—NHAc

RN 627542-26-1 CAPLUS
 CN Propanoic acid, 3-[[[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




RN 627542-28-3 CAPLUS
 CN Carbamic acid, [(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]]bis[2-amino-1-dimethylethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



RN 627542-37-4 CAPLUS
 CN Carbamic acid, [(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[[(5S)-2-oxo-3,5-oxazolidinediyl]methyleneimino(2-oxo-2,1-ethanediyl)]bis[2-amino-1-dimethylethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-40-9 CAPLUS
 CN Acetamide, N,N'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]bis[2-amino-, mono(trifluoroacetate)] (9CI) (CA INDEX NAME)

CM 1

CRN 627542-39-6
 CMF C24 H26 F2 N6 O6

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

-NH2


CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 627542-42-1 CAPLUS
 CN Carbamic acid, [(5S)-3-[4'-(5S)-5-[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-45-4 CAPLUS
 CN Acetamide, 2-amino-N-[(5S)-3-[4'-(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-44-3
 CMF C22 H23 F2 N5 O5

Absolute stereochemistry.




CH 2


CRN 76-05-1
CMF C2 H F3 O2

RN 627542-48-7 CAPLUS
CN 2-Oxazolidinone, 3-[2,2'-difluoro-4'-(5R)-5-(methoxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-[(1,1-dimethylethyl)dimethylsilyl]oxy[methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-52-3 CAPLUS
CN Carbamic acid, [(5S)-3-[4'-(5R)-5-[(1,1-dimethylethyl)dimethylsilyl]ox




RN 627542-70-5 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(methylamino)methyl]-, (5S,5'S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1

CRN 627542-69-2
CMF C22 H24 F2 N4 O4

Absolute stereochemistry.




CH 2

CRN 76-05-1
CMF C2 H F3 O2


627542-60-3 CAPLUS
CN Carbamic acid, [(5S)-3-[4'-(5S)-5-(dimethylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-60-3 CAPLUS
CN Carbamic acid, [(5S)-3-[4'-(5S)-5-(dimethylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-66-9 CAPLUS
CN Carbamic acid, [(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]bis[methyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-72-7 CAPLUS
CN Propanoic acid, 3-[(5S)-3-[4'-(5S)-5-[(1,1-dimethylethoxy)carbonyl]amino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

RN 627542-80-7 CAPLUS
CN Butanoic acid, [(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[(5R)-2-oxo-3,5-oxazolidinediyl]methylene] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 627542-81-8 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-(hydroxymethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-82-9 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-[(methylsulfonyl)oxy]methyl]-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-84-1 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-(aminomethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-85-2 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-(aminomethyl)-, (5S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-87-4 CAPLUS
 CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-88-5 CAPLUS
 CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-89-6 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(5R)-5-[(acetoxy)methyl]-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-95-4 CAPLUS
 CN 1H-Isindole-1,3(2H)-dione, 2-[(5S)-3-[2,2'-difluoro-4'-(5R)-5-[(methoxymethoxy)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

-OMe


RN 627542-96-5 CAPLUS
 CN 2-oxazolidinone, 5-(aminomethyl)-3-[2,2'-difluoro-4'-(5R)-5-[(methoxymethoxy)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-97-6 CAPLUS
 CN Acetamide,
 N-[(5S)-3-[2,2'-difluoro-4'-(5R)-5-[(methoxymethoxy)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724792-86-3 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(5S)-5-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724792-88-5 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(5R)-5-[(acetyloxy)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724792-91-0 CAPLUS
 CN 1H-Isindole-1,3(2H)-dione, 2,2'-(2-fluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 724792-92-1 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2-fluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(aminomethyl)-, (5S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724792-95-4 CAPLUS
 CN carbamic acid, [(5R)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724792-97-6 CAPLUS
 CN carbamic acid, [(5R)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-1,2,5-thiadiazol-3-yl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724793-05-9 CAPLUS
 CN Acetamide, N-[(5R)-3-[4'-([(5R)-5-[(2,3-dihydroxypropano) methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-10-6 CAPLUS
 CN Carbamic acid, [(1S)-3-[4'-(5S)-5-[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-3-isoxazolyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B


—NHAc

RN 724793-21-9 CAPLUS
 CN Acetamide,
 N-[(5S)-3-[4'-([(5R)-5-[(2-(1,3-dihydro-1,3-dioxo-2H-isindol-2-yl)ethoxy)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A



RN 724793-19-5 CAPLUS
 CN Carbamic acid, [(1-[(5R)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-4-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—NHAc

RN 724793-24-2 CAPLUS
 CN Carbamic acid,
 [2-[(1S)-3-[2,2'-difluoro-4'-([(5R)-2-oxo-5-(2H-tetrazol-2-yl)methyl]-3-oxazolidinyl)](1,1'-biphenyl)-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

—OBu-t

RN 724793-27-5 CAPLUS
 CN Carbamic acid,
 [2-[(1S)-3-[2,2'-difluoro-4'-([(5R)-2-oxo-5-(1H-tetrazol-1-yl)methyl]-3-oxazolidinyl)](1,1'-biphenyl)-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI)

Absolute stereochemistry.




PAGE 1-B

OBu-t


RN 724793-30-0 CAPLUS
CN Carbamic acid, [2-{{({(5S)-3-[4'-({(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl}-2,2'-difluoro[1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl]methyl}carbonyl)amino}ethyl}-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B

PAGE 1-A



PAGE 1-B




RN 724793-39-9 CAPLUS
CN Carbamic acid, [(5R)-3-(4'-({(5S)-5-[(1,1-dimethylethoxy)carbonyl]amino}acetyl)amino)methyl]-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl]methyl}-, 1,2,5-thiadiazol-3-yl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

NHAc

RN 724793-33-3 CAPLUS
CN Carbamic acid, [(5S)-3-[4'-({(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl}-2,2'-difluoro[1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl]methyl]2-[(1,1-dimethylethoxy)carbonyl]amino]ethyl}-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

NHAc

RN 724793-36-6 CAPLUS
CN Carbamic acid, [2-{{({(5S)-3-[2,2'-difluoro-4'-[(5R)-2-oxo-5-[(1,2,5-thiadiazol-3-yl)oxy]methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl]methyl}amino}-2-oxoethyl}-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 724793-42-4 CAPLUS
CN Carbamic acid, [(5S)-3-[4'-({(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl}-2,2'-difluoro[1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl]methyl]2-[(1,1-dimethylethoxy)carbonyl]amino]-5-thiazolyl]methyl}-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

-OBu-t


RN 724793-48-0 CAPLUS
 CN 4-Morpholinocarboxylic acid, 2-[[[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]carbonyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B




RN 724793-61-7 CAPLUS
 CN Carbamic acid, [5-[[[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]carbonyl]-1,3-phenylene]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B



RN 724793-50-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[2-[[((5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B




RN 724793-66-2 CAPLUS
 CN Carbamic acid, [(1R)-2-[[[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724793-69-5 CAPLUS
 CN 1-Pyridinedicarboxylic acid, 2-[[[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-75-3 CAPLUS
 CN Acetamide, N-[(5S)-3-(2,2'-difluoro-1,1'-biphenyl)-4,4'-diyl]bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]bis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 501939-79-3P 627541-96-2P 627541-98-4P
 627541-99-5P 627542-01-2P 627542-02-3P
 627542-04-5P 627542-05-7P 627542-10-3P
 627542-11-4P 627542-12-5P 627542-14-7P
 627542-18-1P 627542-19-2P 627542-20-5P
 627542-24-9P 627542-25-0P 627542-27-2P
 627542-32-9P 627542-36-3P 627542-46-5P
 627542-50-1P 627542-55-6P 627542-57-8P
 627542-64-7P 627542-71-6P 627542-74-9P
 627542-75-0P 627542-76-1P 627542-77-2P
 627542-78-3P 627542-79-4P 627542-83-0P
 627542-86-3P 627542-90-9P 627542-98-7P
 627543-00-4P 627543-01-5P 627543-02-6P
 724792-87-4P 724792-89-6P 724792-93-2P
 724792-94-3P 724792-96-5P 724792-99-7P
 724793-04-0P 724793-05-0P 724793-07-1P
 724793-09-3P 724793-12-8P 724793-13-9P
 724793-15-1P 724793-16-2P 724793-18-4P
 724793-20-8P 724793-22-0P 724793-23-1P
 724793-26-4P 724793-29-7P 724793-32-2P


L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Acetamide, N-[(5S)-3-(2,2'-difluoro-4'-(5S)-2-oxo-5-[(1-thioxoethylamino)methyl]-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627541-99-5 CAPLUS
 CN Carbamic acid, [(1S)-2-[(5S)-3-[4'-(5S)-5-((acetylamino)methyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-[(1,1-dimethylethoxy)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-01-2 CAPLUS
 CN Propanamide, N-[(5S)-3-[4'-(5S)-5-((acetylamino)methyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-amino-3-hydroxy-, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 627542-00-1
 CMF C25 H27 F2 N5 O7

724793-35-5P 724793-38-6P 724793-41-3P
 724793-43-5P 724793-47-9P 724793-49-1P
 724793-51-5P 724793-53-7P 724793-55-9P
 724793-57-1P 724793-58-2P 724793-59-3P
 724793-60-6P 724793-63-9P 724793-65-1P
 724793-68-4P 724793-71-9P 724793-73-1P
 724793-74-2P 724793-77-5P 724793-78-6P
 724793-79-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIIOL (Biological study); PREP (Preparation); USES (Uses); (prepn. of (oxepoxazolidinyl)biphenyls as bactericides for drug-resistant bacteria)


RN 501939-79-3 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(hydroxymethyl)-, (5R,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627541-96-2 CAPLUS
 CN Carbamic acid, [(1S)-3-[4'-(5S)-5-((acetylamino)methyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627541-98-4 CAPLUS

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 627542-02-3 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(5S)-5-((aminoiminomethyl)amino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 627542-04-5 CAPLUS
 CN 1H-Imidazole-1-carboxylic acid, 5-[(2S)-3-[[((5S)-3-(4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-2-[(1,1-dimethylethoxy)carbonyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-06-7 CAPLUS
 CN 1H-Imidazole-4-propanamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- α -amino-, (aS)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 627542-05-6
 CMF C28 H29 F2 N7 O6

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

\rightarrow NHAc

CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 627542-10-3 CAPLUS
 CN Pentanamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-amino-5-[(aminoiminomethyl)amino]-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 627542-09-0
 CMF C28 H34 F2 N8 O6

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



\rightarrow NHAc

CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 627542-11-4 CAPLUS
 CN D-Glucopyranuronamide,
 N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, 1,2,3,4-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 627542-12-5 CAPLUS
 CN Carbamic acid,
 [(3S)-4-[[((5S)-3-(4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl)-2-oxo-5-oxazolidinyl)methyl]amino]-3-hydroxy-4-oxobutyl]-, (4-methoxyphenyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 627542-14-7 CAPLUS
 CN Butanamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-4-amino-2-hydroxy-, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-13-6
 CMF C26 H29 F2 N5 O7

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2

RN 627542-18-1 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627542-19-2 CAPLUS

CN 1-Cyclohexene-1-carboxamide,
 N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-3,4,5-trihydroxy-, (3R,4S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-20-5 CAPLUS

CN Propanamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2,3-dihydroxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 627542-24-9 CAPLUS
 CN Propanamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2,3-diamino-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-23-8
 CMF C25 H28 F2 N6 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2


L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 627542-25-0 CAPLUS

CN 2-Oxazolidinone, 5-[(acetoxy)methyl]-3-(2,2'-difluoro-4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627542-27-2 CAPLUS

CN Propanoic acid, 3-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-32-9 CAPLUS

CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(aminomethyl)-, (5S,5'S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-31-8
CNF C20 H20 F2 N4 O4



Absolute stereochemistry.



CM 2

CRN 76-05-1
CNF C2 H F3 O2RN 627542-36-3 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluorobiphenyl)-4,4'-diyl bis[5-(methoxymethyl)-, (SR,S'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 627542-46-5 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-(5S)-5-[(dimethylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluorobiphenyl-4-yl]-2-oxo-5-oxazolidinylmethyl- (9CI) (CA INDEX NAME)

CM 2

CRN 76-05-1
CNF C2 H F3 O2RN 627542-57-8 CAPLUS
CN 2-Oxazolidinone, 3,3'-(2,2'-difluorobiphenyl)-4,4'-diyl bis[5-[(dimethylamino)methyl]-, (SS,S'S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 627542-64-7 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4'-(5S)-5-[(dimethylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluorobiphenyl-4-yl-, (SS)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 627542-63-6
CNF C22 H24 F2 N4 O4

Absolute stereochemistry.

RN 627542-50-1 CAPLUS
CN 2-Oxazolidinone, 3-[2,2'-difluoro-4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-1,1'-biphenyl-4-yl]-5-(methoxymethyl)-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 627542-55-6 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[2,2'-difluoro-4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-1,1'-biphenyl-4-yl-, (SS)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-54-5
CNF C20 H19 F2 N3 O5

Absolute stereochemistry.


Absolute stereochemistry.



CM 2

CRN 76-05-1
CNF C2 H F3 O2RN 627542-71-6 CAPLUS
CN Acetamide, N,N'-(2,2'-difluorobiphenyl)-4,4'-diyl bis[(5S)-2-oxo-3,5-oxazolidinediyl]bis[N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 627542-74-9 CAPLUS
CN Propanoic acid, 3-[(5S)-3-[4'-(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluorobiphenyl-4-yl]-2-oxo-5-oxazolidinediyl]amino-3-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-73-8
CMF C23 H22 F2 N4 O7

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 627542-75-0 CAPLUS
CN Acetamide, N,N'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]bis[2-(acetamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.

—NMe2




Absolute stereochemistry.



RN 627542-79-4 CAPLUS
CN Acetamide,
N-[(5S)-3-(2,2'-difluoro-4'-(5S)-5-(1H-imidazol-1-ylmethyl)-2-oxo-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-

PAGE 1-A




PAGE 1-B

—NHAc


RN 627542-76-1 CAPLUS
CN Acetamide,
2-(acetamino)-N-[(5S)-3-[4'-(5S)-5-[(acetamino)methyl]-2-oxo-3,5-oxazolidinediyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-77-2 CAPLUS
CN Acetamide, N,N'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]bis[2-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-83-0 CAPLUS
CN 2-Oxazolidinone, 3-(2,2'-dimethoxy-4'-(5R)-5-[(methylsulfonyloxy)methyl]-2-oxo-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-86-3 CAPLUS
CN Acetamide,
N,N'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 627542-90-9 CAPLUS

CN Acetamide, N-[(5S)-3-[4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 627542-98-7 CAPLUS

CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 724792-87-4 CAPLUS

CN 1H-Imidazole-2-carboxamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724792-89-6 CAPLUS


CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-(5R)-5-[(methylsulfonyl)amino]methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 627543-00-4 CAPLUS

CN Acetamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]-2-[(aminoiminomethyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627543-01-5 CAPLUS

CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-(5R)-5-[(3-isoxazolyloxy)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 627543-02-6 CAPLUS

CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-(5R)-2-oxo-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 724792-93-2 CAPLUS

CN Acetamide, N,N'-(2-fluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]bis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 724792-94-3 CAPLUS


CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724792-96-5 CAPLUS
 CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-(5S)-5-[(3-isoxazolidinyl)amino]methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724792-98-7 CAPLUS
 CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-(5S)-2-oxo-5-[(1,2,5-thiadiazol-3-ylamino)methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724793-04-8 CAPLUS
 CN Carbamic acid, [(5S)-3-[4'-(5S)-5-[(acetamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-06-0 CAPLUS
 CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-(5R)-5-[(2-hydroxyethoxy)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 724793-07-1 CAPLUS
 CN Carbamic acid, [(5S)-3-[4'-(5S)-5-[(acetamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, 2-[(1,1-dimethylethoxy)carbonyl]amino]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

RN 724793-09-3 CAPLUS
 CN Carbamic acid, [(5S)-3-[4'-(5S)-5-[(acetamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, 2-aminoethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-08-2
 CMF C25 H27 F2 N5 O7



CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 724793-12-8 CAPLUS
 CN Acetamide, 2-amino-N-[(5S)-3-[2,2'-difluoro-4'-(5S)-5-[(3-isoxazolidinyl)amino]methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 724793-11-7
 CMF C25 H24 F2 N6 O6

Absolute stereochemistry.


L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Acetamide, N-[(5S)-3-{4'-(5R)-5-[(2-aminoethoxy)methyl]-2-oxo-3-oxazolidinyl}-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-23-1 CAPLUS
 CN Acetamide, N-[(5S)-3-{2,2'-difluoro-4'-(5S)-2-oxo-5-[(3-pyridinylamino)thiomethyl]amino]methyl}-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724793-26-4 CAPLUS
 CN Acetamide, 2-amino-N-[(5S)-3-{2,2'-difluoro-4'-(5R)-2-oxo-5-(2H-tetrazol-2-ylmethyl)-3-oxazolidinyl}[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-25-3
 CMF C23 H22 F2 N8 O5

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 724793-29-7 CAPLUS
 CN Acetamide, 2-amino-N-[(5S)-3-{2,2'-difluoro-4'-(5R)-2-oxo-5-(1H-tetrazol-1-ylmethyl)-3-oxazolidinyl}[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-28-6
 CMF C23 H22 F2 N8 O5

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 724793-32-2 CAPLUS
 CN Acetamide, N-[(5S)-3-{4'-(5S)-5-[(2-aminoethyl)amino]carbonyl]amino]methyl]-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-31-1
 CMF C25 H28 F2 N6 O6

Absolute stereochemistry.

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 724793-35-5 CAPLUS
 CN Acetamide, N-[(5S)-3-{4'-(5S)-5-[(2-aminoethyl)amino]methyl}-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-34-4
 CMF C24 H27 F2 N5 O5

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 724793-38-8 CAPLUS
CN Acetamide, 2-amino-N-[(5S)-3-[2,2'-difluoro-4'-([(5R)-2-oxo-5-[(1,2,5-thiadiazol-3-yl)oxy]methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 724793-37-7
CMF C24 H22 F2 N6 O6 S

Absolute stereochemistry.



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 724793-41-3 CAPLUS
CN Acetamide, 2-amino-N-[(5S)-3-[2,2'-difluoro-4'-(5S)-2-oxo-5-[(1,2,5-

thiadiazol-3-ylamino)methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 724793-40-2
CMF C24 H23 F2 N7 O5 S

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 724793-43-5 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-(5S)-5-[(2-amino-5-thiazolyl)methyl]amino]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 724793-47-9 CAPLUS
CN 4-Piperidinecarboxamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 724793-46-8
CMF C28 H31 F2 N5 O6

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 724793-49-1 CAPLUS

Absolute stereochemistry.



RN 724793-51-5 CAPLUS
CN 1-Piperazineacetamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 724793-53-7 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-(methylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 724793-52-6
CMF C25 H27 F2 N5 O6

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 724793-55-9 CAPLUS
CN 2-Pyrrrolidinecarboxamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, (2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 724793-54-8
CMF C27 H29 F2 N5 O6

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 724793-57-1 CAPLUS
CN 2-Piperazinecarboxamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 724793-56-0
CMF C27 H30 F2 N6 O6

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 724793-58-2 CAPLUS
CN Pyrazinecarboxamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724793-59-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 724793-60-6 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 724793-63-9 CAPLUS
CN Benzamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-3,5-diamino-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 724793-62-8
CMF C29 H28 F2 N6 O6

Absolute stereochemistry.



CM 2
CRN 76-05-1




RN 724793-65-1 CAPLUS
 CN Propanamide, N-[(5S)-3-(4'-(5S)-5-((acetylamino)methyl)-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-3-amino-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-64-0
 CMF C25 H27 F2 N5 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 724793-68-4 CAPLUS
 CN Propanamide, N-[(5S)-3-(4'-(5S)-5-((acetylamino)methyl)-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-amino-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-67-3
 CMF C25 H27 F2 N5 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 724793-71-9 CAPLUS
 CN 2-Pyrolidinecarboxamide, N-[(5S)-3-(4'-(5S)-5-((acetylamino)methyl)-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-70-8
 CMF C27 H29 F2 N5 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 724793-73-1 CAPLUS
 CN Butanamide, N-[(5S)-3-(4'-(5S)-5-((acetylamino)methyl)-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-amino-4-(methylthio)-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-72-0
 CMF C27 H31 F2 N5 O6 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 724793-74-2 CAPLUS
 CN Acetamide, N,N'-(5,5'-diamino-2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 724793-77-5 CAPLUS
 CN Acetamide, 2-amino-N-[4,4'-bis((5S)-5-((acetylamino)methyl)-2-oxo-3-oxazolidinyl)-2',6-difluoro[1,1'-biphenyl]-3-yl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 724793-76-4
CMF C26 H28 F2 N6 O7

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 724793-78-6 CAPLUS
 CN Carbamic acid, [(1-[(5R)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-1H-1,2,3-triazol-5-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 724793-79-7 CAPLUS

CN Acetamide, N-[(5S)-3-[4'-(5R)-5-[(4-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Not 102(a)
 later than
 FD 11/24/2003

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:929541 CAPLUS
 DOCUMENT NUMBER: 140:5040
 TITLE: Preparation of bis(2-oxoazolidin-3-yl)biphenyl derivatives as antibacterial agents
 INVENTOR(S): Shiokawa, Sojiro; Ishikawa, Makoto; Yanagisawa, Yumiko; Kawaguchi, Masami; Maehashi, Kazunori; Yoshida, Satoshi
 PATENT ASSIGNEE(S): Meiji Seika Kaisha, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 63 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003335762	A2	2003/11/28	JP 2002-144414	2002/05/20
PRIORITY APPLN. INFO.:			JP 2002-144414	2002/05/20

OTHER SOURCE(S): MARPAT 140:5040

GI



AB The title compds. [I: R1-R5 = H, halo, (un)substituted alkoxy; T, Q = halo, OH, NH2, N3, each (un)substituted Cl-8 alkoxy, Cl-8 alkanoyloxy, Cl-8 alkylsulfonyl, Cl-8 alkylsulfonyloxy, mono- or di(Cl-8 alkyl)amino, Cl-8 alkanoylamino, Cl-8 cycloalkenylcarbonylamino, monocyclic (un)saturated heterocyclic carbonylamino, Cl-8 alkylxycarbonylamino, Cl-8 alkylsilyloxy, or N-Cl-8 alkyl-Cl-8 alkylxycarbonylamino] or pharmaco. acceptable salts thereof or hydrates thereof are prepared

These compds. I possess antibacterial activity against sensitive bacteria on which existing drugs are effective as well as multidrug-resistant bacteria such as methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant enterococci (VRE), and Penicillin-resistant *Streptococcus pneumoniae* (PRSP). Thus, 7.5 μ g Et dithioacetate was added to a solution of 15.1 mg 4-[(5S)-5-acetamidomethyl-2-oxooxazolidin-3-yl]-4'-(5S)-5-aminomethyl-2-oxooxazolidin-3-yl)-2,2'-difluorobiphenyl (preparation given) in 0.5 mL DMF and stirred at room temperature for 14 h to give 801 4-[(5S)-5-acetamidomethyl-2-oxooxazolidin-3-yl]-4'-[(5S)-5-thioacetamidomethyl-2-oxooxazolidin-3-yl]-2,2'-difluorobiphenyl (II). II showed min. inhibitory concentration of 0.125 μ g/mL against MRSA and vancomycin-resistant *Enterococcus faecium*.


IT 501939-76-0P 627541-97-3P 627541-99-5P

627542-07-8P 627542-12-5P 627542-15-8P
 627542-17-0P 627542-22-7P 627542-26-1P
 627542-28-3P 627542-37-4P 627542-40-9P
 627542-42-1P 627542-45-4P 627542-48-7P
 627542-52-3P 627542-60-3P 627542-66-9P
 627542-70-5P 627542-72-7P 627542-80-7P
 627542-81-8P 627542-82-9P 627542-84-1P
 627542-85-2P 627542-87-4P 627542-89-6P
 627542-95-4P 627542-96-5P 627542-97-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prep. of bisoxooxazolidinyl)biphenyl derivs. as antibacterial agents)

RN 501939-76-0 CAPLUS

CN 2-oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(acetyloxy)methyl]-, (5R,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627541-97-3 CAPLUS


CN Acetamide, N-[(5S)-3-[4'-(5S)-5-[(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627541-99-5 CAPLUS

CN Carbamic acid, {[(1S)-2-[[[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-




RN 627542-28-3 CAPLUS
 CN Carbamic acid, [(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]]bis[2-amino-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-37-4 CAPLUS
 CN Carbamic acid, [(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[[(5S)-2-oxo-3,5-oxazolidinediyl]methyleneimino(2-oxo-2,1-ethanediyl)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 627542-40-9 CAPLUS
 CN Acetamide, N,N'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[2-amino-, mono(trifluoroacetate)] (9CI) (CA INDEX NAME)

CM 1

CRN 627542-39-6
 CMF C24 H26 F2 N6 O6

Absolute stereochemistry.



—NH2


CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 627542-42-1 CAPLUS
 CN Carbamic acid, [(5S)-3-[4'-(5S)-5-[{[(1,1-dimethylethoxy)carbonyl]amino}acetyl]amino]methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-45-8 CAPLUS
 CN Acetamide, 2-amino-N-[(5S)-3-[4'-(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-44-3
 CMF C22 H23 F2 N5 O5

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 627542-48-7 CAPLUS
 CN 2-Oxazolidinone, 3-[2,2'-difluoro-4'-(5R)-5-(methoxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-52-3 CAPLUS
 CN Carbamic acid, {{(5S)-3-[4'-(5R)-5-[(1,1-dimethylethyl)dimethylsilyl]ox




RN 627542-70-5 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-[(methylamino)methyl]-, (5S,5'S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-69-2

CMF C22 H24 F2 N4 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2


y)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-60-3 CAPLUS
 CN Carbamic acid, [(5S)-3-[4'-(5S)-5-[(dimethylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-66-9 CAPLUS
 CN Carbamic acid, [(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]bis[methyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-72-7 CAPLUS
 CN Propanoic acid, 3-[[{(5S)-3-[4'-(5S)-5-[(1,1-dimethylethoxy)carbonyl]amino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]-methyl]amino]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

Absolute stereochemistry.

RN 627542-80-7 CAPLUS
 CN Butanoic acid, (2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[(5R)-2-oxo-3,5-oxazolidinediyl]methylene] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

OBu-t

PAGE 1-B

RN 627542-81-8 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-(hydroxymethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-82-9 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-[(methylsulfonyl)oxy]methyl]-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 627542-84-1 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-(azidomethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-85-2 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[5-(aminomethyl)-, (5S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 627542-87-4 CAPLUS
 CN 2-Oxazolidinone, 5-(azidomethyl)-3-[4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-89-6 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(5R)-5-[(acetoxy)methyl]-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-95-4 CAPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 2-[(5S)-3-(2,2'-difluoro-4'-(5R)-5-[(methoxymethoxy)methyl]-2-oxo-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-B


RN 627542-96-5 CAPLUS
 CN 2-Oxazolidinone, 5-(aminomethyl)-3-[2,2'-difluoro-4'-(5R)-5-[(methoxymethoxy)methyl]-2-oxo-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-97-6 CAPLUS
 CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-(5R)-5-[(methoxymethoxy)methyl]-2-oxo-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501939-75-9P 501939-79-3P 627541-95-1P
 627541-96-2P 627541-98-4P 627542-00-1P
 627542-01-2P 627542-02-3P 627542-04-5P
 627542-05-6P 627542-06-7P 627542-09-0P
 627542-10-3P 627542-11-4P 627542-13-6P
 627542-14-7P 627542-16-9P 627542-18-1P
 627542-19-2P 627542-20-5P 627542-21-6P
 627542-23-8P 627542-24-9P 627542-25-0P
 627542-27-2P 627542-31-8P 627542-32-9P
 627542-34-1P 627542-36-3P 627542-39-6P
 627542-44-3P 627542-46-5P 627542-50-1P
 627542-54-5P 627542-55-6P 627542-57-8P
 627542-63-6P 627542-64-7P 627542-69-2P
 627542-71-6P 627542-73-8P 627542-74-9P
 627542-75-0P 627542-76-1P 627542-77-2P
 627542-78-3P 627542-79-4P 627542-83-0P
 627542-86-3P 627542-88-5P 627542-90-9P
 627542-98-7P 627542-99-8P 627543-00-4P
 627543-01-5P 627543-02-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of bisoxo-oxazolidinyl)biphenyl derivs. as antibacterial agents)
 RN 501939-75-9 CAPLUS
 CN Acetamide, N-[{2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl}bis[[(5S)-2-oxo-3,5-oxazolidinediyl]methylene]}bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 501939-79-3 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(hydroxymethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627541-95-1 CAPLUS
 CN Acetamide, N-[(5R)-3-[4'-(5R)-5-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627541-96-2 CAPLUS
 CN Carboxamic acid, [(5S)-3-{4'-(5S)-5-[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627541-99-4 CAPLUS
 CN Acetamide, N-[(5S)-3-(2,2'-difluoro-4'-(5S)-2-oxo-5-[(1-thioxoethyl)aminomethyl]-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-00-1 CAPLUS
 CN Propanamide, N-[(5S)-3-{4'-(5S)-5-[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-2-amino-3-hydroxy-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 627542-01-2 CAPLUS
 CN Propanamide, N-[(5S)-3-[4'-(5S)-5-[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinylmethyl]-2-amino-3-hydroxy-, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-00-1
 CMF C25 H27 F2 N5 O7

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 627542-02-3 CAPLUS
 CN Acetamide,
 N-[(5S)-3-(4'-(5S)-5-[(aminoiminomethyl)amino]methyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-04-5 CAPLUS
 CN 1H-Imidazole-1-carboxylic acid, 5-[(2S)-3-[[[(5S)-3-(4'-(5S)-5-(acetylamino)methyl)-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-2-[(1,1-dimethylethoxy)carbonyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- α -amino-, (S)-, mono(trifluoroacetate)
 (9CI) (CA INDEX NAME)

CM 1

CRN 627542-05-6
 CMF C28 H29 F2 N7 O6

Absolute stereochemistry.



PAGE 1-B

\sim NHAc

CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 627542-09-0 CAPLUS
 CN Pentanamide, N-[(5S)-3-(4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-amino-5-[(aminoiminomethyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B

RN 627542-05-6 CAPLUS
 CN 1H-Imidazole-4-propanamide,
 N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- α -amino-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B

\sim NHAc

RN 627542-06-7 CAPLUS
 CN 1H-Imidazole-4-propanamide,
 N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-

PAGE 1-A



PAGE 1-B


\sim NHAc

RN 627542-10-3 CAPLUS
 CN Pentanamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-amino-5-[(aminoiminomethyl)amino]-, (2S)- (9CI) (CA INDEX NAME)

CM 1

CRN 627542-09-0
 CMF C28 H34 F2 N8 O6

Absolute stereochemistry.






CM 2

CRN 76-05-1
CNF C2 H F3 O2

RN 627542-11-4 CAPLUS
 CN D-Glucopyranosamide,
 N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-, 1,2,3,4-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-13-6 CAPLUS
 CN Butanamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-4-amino-2-hydroxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-16-9 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-18-1 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-19-2 CAPLUS
 CN 1-Cyclohexene-1-carboxamide,
 N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-

RN 627542-14-7 CAPLUS
 CN Butanamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-4-amino-2-hydroxy-, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-13-6
CNF C26 H29 F2 N5 O7


Absolute stereochemistry.



CM 2


CRN 76-05-1
CNF C2 H F3 O2

Absolute stereochemistry.




RN 627542-20-5 CAPLUS
 CN Propanamide, N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2,3-dihydroxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-21-6 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-23-8 CAPLUS
 CN Propanamide, N-[(5S)-3-{4'-(5S)-5-[(acetamino)methyl]-2-oxo-3-oxazolidinyl}-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2,3-diamino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-24-9 CAPLUS
 CN Propanamide, N-[(5S)-3-{4'-(5S)-5-[(acetamino)methyl]-2-oxo-3-oxazolidinyl}-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2,3-diamino-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-23-8
 CMF C25 H28 F2 N6 O6

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 627542-25-0 CAPLUS
 CN 2-oxazolidinone, 5-[(acetoxy)methyl]-3-[2,2'-difluoro-4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-27-2 CAPLUS
 CN Propanoic acid, 3-[(5S)-3-{4'-(5S)-5-[(acetamino)methyl]-2-oxo-3-oxazolidinyl}-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-31-8 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(aminomethyl)-, (5S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-32-9 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(aminomethyl)-, (5S,5'S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-31-8
 CMF C20 H20 F2 N4 O4

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 627542-34-1 CAPLUS
 CN Acetamide, N-[(5S)-3-(2,2'-difluoro-4'-(5S)-5-[(methylsulfonyl)amino)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-36-3 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(methoxymethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 627542-39-6 CAPLUS
 CN Acetamide, N,N'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis([(5S)-2-oxo-3,5-oxazolidinediyl]methylene)bis[2-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 627542-46-5 CAPLUS
 CN Acetamide, N-[(5S)-3-[4'-(5S)-5-[(dimethylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-50-1 CAPLUS
 CN 2-Oxazolidinone, 3-[2,2'-difluoro-4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-(methoxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

-NH₂


RN 627542-44-3 CAPLUS
 CN Acetamide, 2-amino-N-[(5S)-3-[4'-(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-54-5 CAPLUS
 CN 2-Oxazolidinone, 5-(aminomethyl)-3-[2,2'-difluoro-4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-55-6 CAPLUS
 CN 2-Oxazolidinone, 5-(aminomethyl)-3-[2,2'-difluoro-4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-54-5
CMF C20 H19 F2 N3 O5

Absolute stereochemistry.




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 627542-57-8 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(dimethylamino)methyl]-, (5S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-63-6 CAPLUS
 CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4'-(5S)-5-[(dimethylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 627542-64-7 CAPLUS


CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4'-(5S)-5-[(dimethylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-, (5S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-63-6

CMF C22 H24 F2 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 627542-69-2 CAPLUS

CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-[(methylamino)methyl]-, (5S,5'S)- (9CI) (CA INDEX NAME)

RN 627542-74-9 CAPLUS


CN Propanoic acid, 3-[(5S)-3-[4'-(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-3-oxo-, mono(trifluoracetate) (9CI) (CA INDEX NAME)

CM 1

CRN 627542-73-8

CMF C23 H22 F2 N4 O7

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2


Absolute stereochemistry.



RN 627542-71-6 CAPLUS

CN Acetamide, N,N'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]bis[N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-73-8 CAPLUS

CN Propanoic acid, 3-[(5S)-3-[4'-(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]amino]-3-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627542-75-0 CAPLUS

CN Acetamide, N,N'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]bis[2-(acetylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

— NHAc

RN 627542-76-1 CAPLUS

CN Acetamide, 2-(acetylamino)-N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-B

— NHAc

RN 627542-76-1 CAPLUS


CN Acetamide, 2-(acetylamino)-N-[(5S)-3-[4'-(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-77-2 CAPLUS
CN Acetamide, N,N'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinyl]methylene]bis[2-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-79-4 CAPLUS
CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-(5S)-5-(1H-imidazol-1-ylmethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B




RN 627542-83-0 CAPLUS
CN 2-Oxazolidinone, 3-[2,2'-dimethoxy-4'-(5R)-5-[(methylsulfonyloxy)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


-NMe₂

RN 627542-78-3 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-(5S)-5-[(acetamido)methyl]-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 627542-86-3 CAPLUS
CN Acetamide, N,N'-(2,2'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinyl]methylene]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-90-9 CAPLUS
CN Acetamide, N-[(5S)-3-[4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-88-5 CAPLUS
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]-2,2'-dimethoxy[1,1'-biphenyl]-4-yl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627542-98-7 CAPLUS
CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627542-99-8 CAPLUS

CN Acetamide,

N-[(5S)-3-[2,2'-difluoro-4'-(5S)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627543-00-4 CAPLUS

CN Acetamide, N-[(5S)-3-[4'-(5S)-5-[(acetylaminomethyl)-2-oxo-3-oxazolidinyl]-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]-2-[(aminoiminomethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627543-01-5 CAPLUS


CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-(5R)-5-[(3-isoxazolyl)oxy]methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 627543-02-6 CAPLUS

CN Acetamide, N-[(5S)-3-[2,2'-difluoro-4'-(5R)-2-oxo-5-[(1,2,5-thiadiazol-3-yloxy)methyl]-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER: 2003:221667 CAPLUS

DOCUMENT NUMBER: 138:238171

TITLE: Preparation of oxazolidinones and/or isoxazolines as

antibacterial agents

INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Swain, Michael Lingard; Hauck, Sheila Irene; Mills, Stuart Dennett

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022824	A1	20030320	WO 2002-GB4120	20020909
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MM, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, T2, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459766	AA	20030320	CA 2002-2459766	20020909
EP 1427711	A1	20040616	EP 2002-765019	20020909
EP 1427711	B1	20050713		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012458	A	20041019	BR 2002-12458	20020909
JP 2005057386	T2	20050317	JP 2003-526899	20020909
US 2005107435	A1	20050519	US 2003-489266	20020909
NZ 200513621	A	20050524	NZ 2002-531621	20020909
CN 1639136	A	20050713	CN 2002-822327	20020909
AT 295902	E	20050715	AT 2002-765019	20020909
PT 1427711	T	20051130	PT 2002-765019	20020909
ES 2244802	T3	20051216	ES 2002-2765019	20020909
ZA 2004001888	A	20050418	ZA 2004-1888	20040308
NO 2004001428	A	20040608	NO 2004-1428	20040405
HK 1065789	A1	20051230	HK 2004-108506	20041029
PRIORITY APPLN. INFO.:			GB 2001-21942	A 20010911
			GB 2002-15420	A 20020704
			WO 2002-GB4120	W 20020909

OTHER SOURCE(S): MARPAT 138:238171

GI

(5S,5S)-N-[3-(4'-(5-(acetylaminomethyl)-2-oxo-5-oxazolidin-3-yl)-2,2'-difluorobiphenyl-4-yl)-2-oxo-5-oxazolidin-3-yl]acetamide (shown as I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, which useful as antibacterial agents, processes for their

manuf. and pharmaceutical compns. contg. them are described. For I: C is for example, 2-oxo-5-oxazolidin-3-yl; R2a to R3b = H and F; R1a and R1b =, for example, hydroxy, -NHC(W)R4, NH(HET-1) and HET-2; wherein W is O or S; R4 is, for example, H, amino, (1-4C)alkyl; HET-1 is, for example, a C-linked 5-membered heterocyclic ring; HET-2 is, for example, an N-linked

5-membered heterocyclic ring. I have good activity against a broad range of Gram-pos. pathogens including organisms known to be resistant to most commonly used antibiotics, together with activity against fastidious Gram neg. pathogens such as H. influenzae, M. catarrhalis, Mycoplasma and Chlamydia strains. The min. inhibitory concns. of II for methicillin sensitive and quinolone sensitive

Staphylococcus aureus, methicillin resistant and quinolone resistant Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis are 0.25, 0.5, 0.06, 0.13, 2.0 and 0.5 μ g/mL, resp. Preps. of 64 examples of I and many intermediates are included. For example, I was prep'd. as follows:

(5S)-N-[3-(3-fluoro-4-iodophenyl)-2-oxo-5-oxazolidin-3-yl]acetamide (0.4 mmol) and Bu4NBr (0.4 mmol) were stirred in a mixt. of DME (0.5 mL) and NEt3 (2 mmol), and degassed by bubbling N2. Pd(II) acetate (0.04

mmol) was added, and the whole heated at 70° for 18 h. Workup gave the desired product (47 mg). Nine examples of pharmaceutical dosage forms

are tabulated.

IT 501939-76-0P, Acetic acid (5R,5'R)-3-[4'-(5-acetoxymethyl)-2-

oxo-5-oxazolidin-3-yl]-2,2'-difluorobiphenyl-4-yl]-2-oxo-5-oxazolidin-3-yl]acetamide (501940-31-4P), (5R)-5-[(tert-Butyldimethylsilyl)oxy]methyl

]-3-[4'-(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-

oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-3-oxazolidin-2-one

RI: P4C (Pharmacological activity); RCT (Reactant); SPN (Synthetic

Preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate); preparation of oxazolidinones and/or isoxazolines as

antibacterial agents)


RN 501939-76-0 CAPLUS

CN 2-Oxa-oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis(5-

[(acetyl)oxy]methyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

8/4




RN 501940-31-4 CAPLUS
 CN 2-Oxazolidinone, 5-[(1,1-dimethylethyl)dimethylsilyl]oxy)methyl]-3-[4'-(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl][1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501939-75-9P, (5S,5'S)-N-[(3-[4'-(5-[(Acetylamino)methyl]-2-oxooxazolidin-3-yl)-2',2'-difluorobiphenyl-4-yl]-2-oxooxazolidin-5-yl)methyl]acetamide 501939-79-3P, (5R,5'R)-4,4'-Bis(5-hydroxymethyl-2-oxooxazolidin-3-yl)-2',2'-difluorobiphenyl 501939-80-6P, (5S,5'S)-4,4'-Bis(5-[(isoxazol-3-ylamino)methyl]-2-oxooxazolidin-3-yl)-2',2'-difluorobiphenyl 501939-93-1P, (5R,5'R)-4,4'-Bis(5-(1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2',2'-difluorobiphenyl 501940-25-6P, (5S,5'S)-N-[(3-[4'-(5-(Acetylamino)methyl)-2-oxooxazolidin-3-yl)-1,1'-biphenyl-4-yl]-2-oxooxazolidin-5-yl)methyl]acetamide 501940-26-7P, (5R,5'R)-3-(2,2'-Difluoro-4'-(5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl)-1,1'-biphenyl-4-yl)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-2-one 501940-29-0P, (5R)-5-(Hydroxymethyl)-3-(4'-(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl)-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one 501940-33-6P 501940-34-7P, N-[(5S)-3-[4'-(5R)-5-(Acetylamino)methyl)-2-oxo-1,3-oxazolidin-3-yl]-2,2'-[(tert-Butyldimethylsilyl)oxy)methyl]-2-oxo-1,3-oxazolidin-3-yl]-2,2'-



RN 501939-93-1 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501940-25-6 CAPLUS
 CN Acetamide, N,N'-(1,1'-biphenyl)-4,4'-diylbis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]bis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L14 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 difluoro-1,1'-biphenyl-4-yl]-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide 501940-37-0P, (5R)-3-[2-Fluoro-4'-(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one 501940-38-1P, (5R)-5-(Hydroxymethyl)-3-4'-(5R)-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl]-1,1'-biphenyl-4-yl]-1,3-oxazolidin-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of oxazolidinones and/or isoxazolines as antibacterial agents)


RN 501939-75-9 CAPLUS
 CN Acetamide, N,N'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(5S)-2-oxo-3,5-oxazolidinediyl)methylene]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-79-3 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis(5-(hydroxymethyl)-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501939-80-6 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(3-isoxazolylamino)methyl]-, (5S,5'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-26-7 CAPLUS
 CN 2-Oxazolidinone, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R,5'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-29-0 CAPLUS
 CN 2-Oxazolidinone, 3-(4'-(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl)[1,1'-biphenyl]-4-yl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-33-6 CAPLUS
 CN 2-Oxazolidinone, 5-[(1,1-dimethylethyl)dimethylsilyloxy]methyl-3-[2'-fluoro-4'-(4-methyl-1H-1,2,3-triazol-1-yl)methyl-2-oxo-3-oxazolidinyl[1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-34-7 CAPLUS
 CN Acetamide, N-[(5S)-3-(4'-(4-methyl-1H-1,2,3-triazol-1-yl)methyl-2-oxo-3-oxazolidinyl)-2,2'-difluoro[1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-37-0 CAPLUS
 CN 2-Oxazolidinone, 3-[2-fluoro-4'-(4-methyl-1H-1,2,3-triazol-1-yl)methyl-2-oxo-3-oxazolidinyl[1,1'-biphenyl]-4-yl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501940-38-1 CAPLUS
 CN 2-Oxazolidinone, 5-(hydroxymethyl)-3-[4'-(4-methyl-1H-1,2,3-triazol-1-yl)methyl-2-oxo-3-oxazolidinyl[1,1'-biphenyl]-4-yl]-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501939-81-7P, N-(5R,5'R)-{[3-[4'-(5-[(tert-Butoxycarbonyl)isoxazol-3-yl]amino)methyl]-2-oxooxazolidin-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl}-2-oxooxazolidin-5-yl)methyl-N-(isoxazol-3-yl)carbamic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of oxazolidinones and/or isoxazolines as antibacterial agents)
 RN 501939-81-7 CAPLUS
 CN Carbamic acid, [[2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl]bis[3-isoxazolyl- bis(1,1-dimethylethyl)ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS FORMAT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	49.21	551.12
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-6.75	-6.75

STN INTERNATIONAL LOGOFF AT 08:01:10 ON 18 MAY 2006

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:221667 CAPLUS
 DOCUMENT NUMBER: 138:238171
 TITLE: Preparation of oxazolidinones and/or isoxazolines as
 antibacterial agents
 INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Swain,
 Michael Lingard; Hauck, Sheila Irene; Mills, Stuart
 Dennett
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 127 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION: *Oliver J. Carter*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022824	A1	20030120	WO 2002-GB4120	20020909
W: AE, AG, AL, AM, AT, AU, A, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, T2, RW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459766	AA	20030320	CA 2002-2459766	20020909
EP 1427711	A1	20040616	EP 2002-765019	20020909
EP 1427711	BI	20050713		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012458	A	20041019	BR 2002-12458	20020909
JP 2005507386	T2	20050317	JP 2003-526899	20020909
US 2005107435	A1	20050519	US 2003-489266	20020909
NZ 531621	A	20050624	NZ 2002-531621	20020909
CN 1639136	A	20050713	CN 2002-822327	20020909
AT 299502	E	20050715	AT 2002-765019	20020909
PT 1427711	T	20051130	PT 2002-765019	20020909
ES 2244802	T3	20051216	ES 2002-2765019	20020909
ZA 2004001888	A	20050418	ZA 2004-1888	20040308
NO 2004001428	A	20040608	NO 2004-1428	20040405
HK 1065789	A1	20051230	HK 2004-108506	20041029
PRIORITY APPLN. INFO.:				
GB 2001-21942	A	20010911		
GB 2002-15420	A	20020704		
WO 2002-GB4120	W	20020909		

OTHER SOURCE(S): MARPAT 138:238171
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
 AB Oxazolidinones and isoxazolines (shown as I; variables defined below; e.g.

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (5S,5S')-N-(3-[4'-(5-(acetylaminomethyl)-2-oxooxazolidin-3-yl)-2,2'-difluorobiphenyl-4-yl]-2-oxooxazolidin-5-ylmethyl)acetamide (shown as II), or a pharmaceutically-acceptable salt or an in-vivo-hydrolyzable ester thereof, which useful as antibacterial agents, processes for their manuf. and pharmaceutical compns. contg. them are described. For I: C is for example III, IV, V; wherein A and B = 2-oxooxazolidin-3-yl, 2-isoxazolin-3-yl; R2a to R3b = H and F; R1a and R1b, for example, hydroxy, -NHC(W)R4, NH(HET-1) and HET-2; wherein W is O or S; R4 is, for example, H, amino, (1-4C)alkyl; HET-1 is, for example, a C-linked 5-membered heteroaryl ring; HET-2 is, for example, an N-linked

5-membered, fully or partially unsatd. heterocyclic ring. I have good activity against a broad range of Gram-pos. pathogens including organisms known to be resistant to most commonly used antibiotics, together with activity against fastidious Gram neg. pathogens such as *H. influenzae*, *M. catarrhalis*, *Mycoplasma* and *Chlamydia* strains. The min. inhibitory concns. of II for methicillin sensitive and quinolone sensitive *Staphylococcus aureus*, methicillin resistant and quinolone resistant *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Haemophilus influenzae*, and *Moraxella catarrhalis* are 0.25, 0.5, 0.06, 0.13, 2.0 and 0.5 μ g/mL, resp. Preps. of 64 examples of I and many intermediates are included. For example, I was prep'd. as follows:

(5S)-N-[(3-(3-fluoro-4-iodophenyl)-2-oxooxazolidin-5-yl)methyl]acetamide (0.4 mmol) and BU4NBr (0.4 mmol) were stirred in a mixt. of DMF (0.5 mL)

and NEt3 (2 mmol), and degassed by bubbling N₂ (0.04 mmol)

was added, and the whole heated at 70° for 18 h. Workup gave the desired product (47 mg). Nine examples of pharmaceutical dosage forms


are tabulated.

IT 501940-05-2P, N-[(3-[2,2'-Difluoro-4'-(5-acetamidomethyl-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-4,5-dihydroisoxazol-5-yl)methyl]acetamide 501940-08-5P, 1-[(3-[2,2'-Difluoro-4'-(5-(4-methyl-1H-1,2,3-triazol-1-yl)methyl)-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl]-4,5-dihydroisoxazol-5-yl)methyl]acetamide 501940-16-5P, [3-(2,2'-Difluoro-4'-(5-hydroxymethyl-4,5-dihydroisoxazol-3-yl)-1,1'-biphenyl-4-yl)-4,5-dihydroisoxazol-5-yl]methanol

RL: PAC (pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of oxazolidinones and/or isoxazolines as antibacterial agents)


RN 501940-05-2 CAPLUS

CN Acetamide,
 N,N'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[(4,5-dihydro-3,5-isoxazolediyl)methylene]bis-(9CI) (CA INDEX NAME)




L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 501940-08-5 CAPLUS
 CN Isoxazole,
 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[4,5-dihydro-5-(4-methyl-1H-1,2,3-triazol-1-yl)methyl] (9CI) (CA INDEX NAME)




RN 501940-16-5 CAPLUS
 CN 5-Isoxazolemethanol,
 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[4,5-dihydro- (9CI) (CA INDEX NAME)



IT 501940-24-5P, 3-[4'-(5-[(tert-Butyldimethylsilyl)oxy]methyl)-4,5-dihydroisoxazol-3-yl]-2,2'-difluoro-1,1'-biphenyl-4-yl-5-[(tert-butyldimethylsilyl)oxy]methyl-4,5-dihydroisoxazole
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of oxazolidinones and/or isoxazolines as antibacterial agents)
 RN 501940-24-5 CAPLUS
 CN Isoxazole, 3,3'-(2,2'-difluoro[1,1'-biphenyl]-4,4'-diyl)bis[5-[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl-4,5-dihydro- (9CI) (CA INDEX NAME)

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT